Donaldson Filters Up Growth with Bioprocessing Acquisitions
Ticker: DCI · Form: 10-K · Filed: Sep 26, 2025 · CIK: 29644
Sentiment: mixed
Topics: Filtration, Bioprocessing, Industrial Manufacturing, Mobile Solutions, Life Sciences, Acquisitions, Global Markets
Related Tickers: DCI, ITW, PNR, XOM
TL;DR
**DCI is making a smart, aggressive play into bioprocessing, which should boost long-term growth and margins, making it a buy for patient investors.**
AI Summary
Donaldson Company, Inc. (DCI) reported fiscal year 2025 net sales of $3.6 billion, with Mobile Solutions contributing 62.1% ($2.23 billion), Industrial Solutions 29.9% ($1.08 billion), and Life Sciences 8.0% ($288 million). The company is strategically focused on extending market access, expanding technologies, and pursuing strategic acquisitions, particularly in the high-margin bioprocessing sector. Key acquisitions in Life Sciences include Isolere Bio, Inc. and Univercells Technologies in fiscal year 2023, and Solaris Biotechnology S.r.l. and Purilogics LLC in fiscal year 2022, aimed at strengthening its bioprocessing capabilities with disruptive technologies like IsoTag reagents and Purexa membrane chromatography. Risks include reliance on OEM relationships and the cyclical nature of end markets like construction and mining. The strategic outlook emphasizes organic and inorganic growth in bioprocessing, strengthening alternative power solutions, and enhancing digital service offerings to drive profitable growth.
Why It Matters
Donaldson's strategic pivot into Life Sciences, particularly bioprocessing, diversifies its revenue streams beyond traditional industrial and mobile filtration, which are susceptible to economic cycles in construction and mining. This move positions DCI to capitalize on the rapidly expanding cell and gene therapy market, offering investors exposure to high-growth, high-margin segments. For employees, it signals investment in advanced technologies and potential for new skill development. Customers in biopharma benefit from innovative purification and manufacturing solutions, while the broader market sees a traditional industrial player adapting to future-proof its business against competitors by leveraging its core filtration expertise in new, critical applications.
Risk Assessment
Risk Level: medium — The company's Mobile Solutions segment still accounts for 62.1% of net sales, making DCI susceptible to cyclical downturns in construction, mining, agriculture, and transportation markets. While the Life Sciences segment is a growth area, it only represents 8.0% of fiscal 2025 net sales, indicating a significant portion of revenue remains tied to more volatile industrial sectors.
Analyst Insight
Investors should monitor DCI's integration of its recent bioprocessing acquisitions and the growth trajectory of its Life Sciences segment. A successful expansion into bioprocessing could significantly de-risk the company's reliance on cyclical industrial markets and justify a higher valuation.
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Mobile Solutions | $2.23 billion | |
| Industrial Solutions | $1.08 billion | |
| Life Sciences | $288 million |
Key Numbers
- $3.6B — Total Net Sales (Fiscal year 2025 net sales)
- 62.1% — Mobile Solutions Net Sales Share (Represents the largest segment of net sales in fiscal 2025)
- 29.9% — Industrial Solutions Net Sales Share (Second largest segment of net sales in fiscal 2025)
- 8.0% — Life Sciences Net Sales Share (Smallest but strategically growing segment of net sales in fiscal 2025)
- 44.2% — U.S. and Canada Revenue Share (Largest regional revenue contributor in fiscal 2025)
- 27.8% — EMEA Revenue Share (Second largest regional revenue contributor in fiscal 2025)
- 115,907,357 — Shares Outstanding (As of September 12, 2025)
Key Players & Entities
- DONALDSON Company, Inc. (company) — registrant
- Isolere Bio, Inc. (company) — acquired in fiscal year 2023
- Univercells Technologies (company) — acquired in fiscal year 2023
- Solaris Biotechnology S.r.l. (company) — acquired in fiscal year 2022
- Purilogics LLC (company) — acquired in fiscal year 2022
- New York Stock Exchange (regulator) — exchange for DCI common stock
- $8,462,489,351 (dollar_amount) — aggregate market value of voting and non-voting common stock held by non-affiliates as of January 31, 2025
- $71.19 (dollar_amount) — closing price of common stock on January 31, 2025
FAQ
What are Donaldson Company, Inc.'s main business segments?
Donaldson Company, Inc. operates through three main reportable segments: Mobile Solutions, Industrial Solutions, and Life Sciences. In fiscal year 2025, Mobile Solutions accounted for 62.1% of net sales, Industrial Solutions for 29.9%, and Life Sciences for 8.0%.
How is Donaldson expanding its Life Sciences segment?
Donaldson is expanding its Life Sciences segment through strategic acquisitions and organic growth. Notable acquisitions include Isolere Bio, Inc. and Univercells Technologies in fiscal year 2023, and Solaris Biotechnology S.r.l. and Purilogics LLC in fiscal year 2022, all focused on bioprocessing equipment and consumables.
What are the key growth drivers for Donaldson's Mobile Solutions segment?
Key growth drivers for Donaldson's Mobile Solutions segment include providing solutions for higher performance requirements, utilizing technology to improve efficiencies and fuel economies, and increased new equipment production and activity in construction, transportation, agriculture, and mining markets.
What is Donaldson's strategy for profitable growth?
Donaldson's strategy for profitable growth involves three primary priorities: extending market access by growing presence in bioprocessing and alternative power solutions, expanding technologies and solutions through enhanced digital experiences and connected service offerings, and pursuing strategic acquisitions in high-margin areas like bioprocessing.
What is the market value of Donaldson's common stock held by non-affiliates?
As of January 31, 2025, the aggregate market value of voting and non-voting common stock held by non-affiliates of Donaldson Company, Inc. was $8,462,489,351, based on a closing price of $71.19 on the New York Stock Exchange.
What are the primary risks Donaldson faces in its business operations?
Donaldson faces risks including its significant reliance on the cyclical nature of its Mobile Solutions segment, which constitutes 62.1% of fiscal 2025 net sales, making it vulnerable to economic fluctuations in construction, mining, agriculture, and transportation markets.
How does Donaldson's iCue Connected Filtration Technology benefit customers?
Donaldson's iCue Connected Filtration Technology proactively monitors a facility's dust collection equipment to reduce unplanned downtime, supporting efficient operation and maintenance costs. This technology also enhances Donaldson's connection with end-market customers, enabling additional service opportunities.
What percentage of Donaldson's fiscal 2025 revenue came from the U.S. and Canada?
In fiscal year 2025, 44.2% of Donaldson Company, Inc.'s revenue was generated from the U.S. and Canada region, making it the largest contributing region.
What types of products does Donaldson offer in its Industrial Solutions segment?
The Industrial Solutions segment offers a wide range of products including industrial air filtration systems (dust, fume, mist collectors), industrial gases purification systems, industrial hydraulics filtration, power generation air inlet systems, and aerospace and defense filtration products.
What is the significance of Donaldson's acquisition of Purilogics LLC?
Donaldson's acquisition of Purilogics LLC in fiscal year 2022 brought novel Purexa membrane chromatography products for the purification and streamlined manufacturing of biopharmaceuticals, including pDNA, mRNA, and mAbs, offering significant competitive advantages in productivity, speed, and production costs.
Risk Factors
- Reliance on OEM Relationships [high — market]: The company relies on Original Equipment Manufacturer (OEM) relationships for a significant portion of its Mobile Solutions segment. A substantial loss of business from any major OEM could materially impact sales and profitability.
- Cyclicality of End Markets [medium — market]: Key end markets for Mobile Solutions, such as construction and mining, are cyclical and subject to economic downturns. Reduced demand in these sectors can negatively affect sales volumes and financial performance.
- Supply Chain Disruptions [medium — operational]: The company's global operations and manufacturing depend on a complex supply chain. Disruptions due to geopolitical events, natural disasters, or supplier issues could impact production and delivery timelines.
- Cybersecurity Threats [medium — operational]: As a global technology-led company, Donaldson is exposed to cybersecurity risks. A breach could compromise sensitive data, disrupt operations, and damage its reputation.
- Integration of Acquisitions [medium — financial]: The company's strategy includes pursuing strategic acquisitions, particularly in the Life Sciences segment. The successful integration of these acquired businesses, such as Isolere Bio and Univercells Technologies, is critical for realizing their expected benefits and avoiding integration costs or disruptions.
Industry Context
Donaldson operates as a global leader in technology-led filtration solutions across diverse industries. The competitive landscape involves companies offering specialized filtration products and services, with a growing emphasis on advanced technologies and digital integration. Key industry trends include the expansion into high-growth sectors like bioprocessing and the development of solutions for alternative power sources.
Regulatory Implications
While specific regulatory risks are not detailed in the provided text, companies in the filtration industry must comply with environmental regulations related to emissions and product safety standards. Compliance with these regulations is essential for maintaining market access and avoiding penalties.
What Investors Should Do
- Monitor Life Sciences segment growth and acquisition integration.
- Assess impact of OEM relationships and market cyclicality.
- Evaluate expansion of digital and connected services.
Glossary
- OEM
- Original Equipment Manufacturer. A company that manufactures products based on the design or brand of another company. (Donaldson sells filtration products to OEMs in various industries, making these relationships crucial for its Mobile Solutions segment.)
- Bioprocessing
- The use of biological processing equipment and techniques to manufacture products, often in the pharmaceutical and biotechnology industries. (Donaldson is strategically investing in and acquiring companies within the bioprocessing sector to drive growth in its Life Sciences segment.)
- Aftermarket
- The market for replacement parts and services for products that have already been sold. (Donaldson aims to expand its aftermarket share, particularly in Industrial Solutions, by enhancing connected service offerings.)
- IsoTag reagents
- Proprietary reagents used in bioprocessing, likely for cell and gene therapy applications. (These are examples of disruptive technologies acquired by Donaldson to strengthen its bioprocessing capabilities.)
- Purexa membrane chromatography
- A type of filtration technology used in bioprocessing for purifying biological molecules. (This technology, acquired through Purilogics LLC, enhances Donaldson's offerings in the high-growth bioprocessing market.)
Year-Over-Year Comparison
The provided text focuses on fiscal year 2025 performance and strategic priorities. A comparison to the previous filing would require data from the fiscal year 2024 10-K. Key metrics such as revenue growth, changes in segment contributions, and the impact of recent acquisitions (Isolere Bio, Univercells, Solaris Biotechnology, Purilogics) on financial performance and risk profile would be areas of interest for comparison.
Filing Stats: 4,105 words · 16 min read · ~14 pages · Grade level 16 · Accepted 2025-09-26 12:22:56
Key Financial Figures
- $5.00 — ange on which registered Common Stock, $5.00 par value DCI New York Stock Exchange
- $71.19 — ,489,351 (based on the closing price of $71.19 as reported on the New York Stock Excha
- $552.2 million — days as of July 31, 2025 and 2024 were $552.2 million and $574.7 million, respectively. Sea
- $574.7 m — , 2025 and 2024 were $552.2 million and $574.7 million, respectively. Seasonality Man
- $87.8 m — 2025, 2024 and 2023, the Company spent $87.8 million, $93.6 million and $78.1 million,
- $93.6 million — 2023, the Company spent $87.8 million, $93.6 million and $78.1 million, respectively, on res
- $78.1 m — spent $87.8 million, $93.6 million and $78.1 million, respectively, on research and de
Filing Documents
- dci-20250731.htm (10-K) — 2361KB
- exhibit21dci20250731.htm (EX-21) — 30KB
- exhibit23dci20250731.htm (EX-23) — 3KB
- exhibit24dci20250731.htm (EX-24) — 48KB
- exhibit31-adci20250731.htm (EX-31.A) — 12KB
- exhibit31-bdci20250731.htm (EX-31.B) — 12KB
- exhibit32dci20250731.htm (EX-32) — 12KB
- dci-20250731_g1.jpg (GRAPHIC) — 10KB
- dci-20250731_g2.jpg (GRAPHIC) — 270KB
- dci-20250731_g3.jpg (GRAPHIC) — 1755KB
- dci-20250731_g4.jpg (GRAPHIC) — 96KB
- dci-20250731_g5.jpg (GRAPHIC) — 55KB
- dci-20250731_g6.jpg (GRAPHIC) — 56KB
- dci-20250731_g7.jpg (GRAPHIC) — 54KB
- dci-20250731_g8.jpg (GRAPHIC) — 52KB
- 0000029644-25-000098.txt ( ) — 19504KB
- dci-20250731.xsd (EX-101.SCH) — 77KB
- dci-20250731_cal.xml (EX-101.CAL) — 123KB
- dci-20250731_def.xml (EX-101.DEF) — 465KB
- dci-20250731_lab.xml (EX-101.LAB) — 1087KB
- dci-20250731_pre.xml (EX-101.PRE) — 825KB
- dci-20250731_htm.xml (XML) — 2592KB
Business
Business 1 Item 1A.
Risk Factors
Risk Factors 11 Item 1B. Unresolved Staff Comments 15 Item 1C. Cybersecurity 15 Item 2.
Properties
Properties 16 Item 3.
Legal Proceedings
Legal Proceedings 16 Item 4. Mine Safety Disclosures 16 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 16 Item 6. [Reserved] 18 Item 7.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 18 Item 7A.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 33 Item 8.
Financial Statements and Supplementary Data
Financial Statements and Supplementary Data 35 Report of Independent Registered Public Accounting Firm 35 Consolidated Statements of Earnings 37 Consolidated Statements of Comprehensive Income 38 Consolidated Balance Sheets 39 Consolidated Statements of Cash Flows 40 Consolidated Statements of Changes in Stockholders' Equity 41
Notes to Consolidated Financial Statements
Notes to Consolidated Financial Statements 42 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 72 Item 9A.
Controls and Procedures
Controls and Procedures 72 Item 9B. Other Information 73 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 73 PART III Item 10. Directors, Executive Officers and Corporate Governance 73 Item 11.
Executive Compensation
Executive Compensation 73 Item 12.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 73 Item 13. Certain Relationships and Related Transactions and Director Independence 73 Item 14. Principal Accountant Fees and Services 73 PART IV Item 15. Exhibits and Financial Statement Schedules 74 Item 16. Form 10-K Summary 76
Business
Item 1. Business The Company Founded in 1915, Donaldson Company, Inc. (the Company or Donaldson) is a global leader in technology-led filtration products and solutions, serving a broad range of industries and advanced markets. Donaldson's diverse and skilled employees at more than 150 locations on six continents, 77 of which are manufacturing and/or distribution centers, partner with customers — from small business owners to the world's largest original equipment manufacturer (OEM) brands — to solve complex filtration challenges. Customers choose Donaldson's filtration solutions due to their stringent technical and performance requirements, the need for reliability and the value proposition of Donaldson's solutions and/or services. Donaldson's four regions and their contributing share of fiscal year 2025 revenue are as follows: the U.S. and Canada 44.2%; Europe, Middle East and Africa (EMEA) 27.8%; Asia Pacific (APAC) 17.2%; and Latin America (LATAM) 10.8%. Below are the Company's manufacturing plants and distribution centers by region. Strategic Priorities The Company has three primary strategic priorities to drive profitable growth. Below are each of the priorities and areas of focus related to each priority. Extend Market Access - Grow Addressable Market by Extending Presence Across Adjacencies Significantly grow presence in bioprocessing markets organically and inorganically within Life Sciences segment Strengthen position across alternative power solutions through innovated and differentiated products Expand Technologies and Solutions - Leverage Foundational Filtration Capabilities to Expand Best-in-class Technology and Service Offerings Expand Industrial Solutions connected service offerings to gain additional aftermarket share Enhance digital experience through stronger data integration and navigation capabilities Pursue Strategic Acquisitions - Accelerate Long-term Growth Through Strategic Acquisitions in High-margin Areas Strengthen presence